These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 6529759)

  • 1. [Comparison of the biological availability of levodopa in the preparations Dopaflex and Nakom in patients with parkinson disease].
    Terziivanov D; Havlík I; Stika L; Janků I
    Cesk Farm; 1984 Feb; 33(1):20-3. PubMed ID: 6529759
    [No Abstract]   [Full Text] [Related]  

  • 2. Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients.
    Sasahara K; Nitanai T; Habara T; Morioka T; Nakajima E
    J Pharm Sci; 1980 May; 69(3):261-5. PubMed ID: 7381698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
    Di Rocco A; Werner P
    Ann Neurol; 2000 Jan; 47(1):136-7. PubMed ID: 10632116
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa.
    Durso R; Evans JE; Josephs E; Szabo GK; Evans BA; Handler JS; Jennings D; Browne TR
    Ann Neurol; 1997 Sep; 42(3):300-4. PubMed ID: 9307250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
    Deleu D; Jacob P; Chand P; Sarre S; Colwell A
    Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing bioavailability in the treatment of Parkinson's disease.
    Seeberger LC; Hauser RA
    Neuropharmacology; 2007 Dec; 53(7):791-800. PubMed ID: 17936857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Senile Parkinsonism and dopa pharmacokinetics.
    Broe GA; Evans MA; Triggs EJ
    Clin Exp Neurol; 1981; 18():174-9. PubMed ID: 6926387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 13. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
    Julien C; Berthiaume L; Hadj-Tahar A; Rajput AH; Bédard PJ; Di Paolo T; Julien P; Calon F
    Neurochem Int; 2006 Apr; 48(5):404-14. PubMed ID: 16442670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial treatment of Parkinson disease: levodopa or dopamine agonists.
    Weiner WJ
    Arch Neurol; 2004 Dec; 61(12):1966-9. PubMed ID: 15596623
    [No Abstract]   [Full Text] [Related]  

  • 16. Initial Parkinson disease therapy: levodopa, dopamine agonists, or both?
    Roach ES
    Arch Neurol; 2004 Dec; 61(12):1972-3. PubMed ID: 15596625
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
    Rodgers KJ; Hume PM; Morris JG; Dean RT
    J Neurochem; 2006 Aug; 98(4):1061-7. PubMed ID: 16771833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
    Okereke CS
    J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels].
    Lökk J
    Lakartidningen; 2003 Aug; 100(35):2674-7. PubMed ID: 14531126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
    Kamenetskiĭ VK
    Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.